Noninvasive indices of fibrosis in NAFLD: Starting to think about a three-hit (at least) phenomenon

American Journal of Gastroenterology

Volumn 102, Issue 2, 2007, Pages 409-411

  Charlton, Michael ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEHAVIOR; DISEASE COURSE; DISEASE SEVERITY; ENVIRONMENT; FATTY LIVER; GENE EXPRESSION; GENE INTERACTION; GENETIC SUSCEPTIBILITY; HISTOLOGY; HUMAN; INFLAMMATION; LIVER DISEASE; LIVER FIBROSIS; NONALCOHOLIC FATTY LIVER; PATIENT; PHENOTYPE; PRIORITY JOURNAL; REVIEW; RISK;

BIOPSY; DISEASE PROGRESSION; FATTY LIVER; HUMANS; LIVER CIRRHOSIS; PREVALENCE; PROGNOSIS; RISK FACTORS; SEVERITY OF ILLNESS INDEX;

EID: 33846529926     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1111/j.1572-0241.2006.01039.x     Document Type: Review

References (14)

1. Adams LA, Lymp JF, St Sauver J, et al. The natural history of nonalcoholic fatty liver disease: A population-based cohort study [see comment]. Gastroenterology 2005;129:113-21.
2. Abdelmalek MF, Angulo P, Jorgensen RA, et al. Betaine, a promising new agent for patients with nonalcoholic steatohepatitis: Results of a pilot study [comment]. Am J Gastroenterol 2001;96:2711-7.
3. Clark JM, Diehl AM. Nonalcoholic fatty liver disease: An underrecognized cause of cryptogenic cirrhosis. JAMA 2003;289:3000-4.
4. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med 2002;346:1221-31.
5. Wanless IR, Lentz JS. Fatty liver hepatitis (steatohepatitis) and obesity: An autopsy study with analysis of risk factors. Hepatology 1990;12:1106-10.
6. Pinto HC, Baptista A, Camilo ME, et al. Nonalcoholic steatohepatitis. Clinicopathological comparison with alcoholic hepatitis in ambulatory and hospitalized patients. Dig Dis Sci 1996;41:172-9.
7. Charlton M. Nonalcoholic fatty liver disease: A review of current understanding and future impact. Clin Gastroenterol Hepatol 2004;2:1048-58.
8. Chien KL, Hsu HC, Chao CL, et al. Interaction of obesity, metabolic syndrome and Framingham risk on steatohepatitis among healthy Taiwanese: Population-based nested case-control study. Cardiovasc Diabetol 2006;5:12.
9. Palekar NA, Naus R, Larson SP, et al. Clinical model for distinguishing nonalcoholic steatohepatitis from simple steatosis in patients with nonalcoholic fatty liver disease. Liver Int 2006;26:151-6.
10. Angulo P, Keach JC, Batts KP, et al. Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis. Hepatology 1999;30:1356-62.
11. Suzuki A, Angulo P, Lymp J, et al. Hyaluronic acid, an accurate serum marker for severe hepatic fibrosis in patients with non-alcoholic fatty liver disease. Liver Int 2005;25:779-86.
12. Wieckowska A, Zein NN, Yerian LM, et al. In vivo assessment of liver cell apoptosis as a novel biomarker of disease severity in nonalcoholic fatty liver disease. Hepatology 2006;44:27-33.
13. Day CP, James OF. Steatohepatitis: A tale of two "hits"? Gastroenterology 1998;114:842-5.
14. Huang H, Shiffman ML, Cheung RC, et al. Identification of two gene variants associated with risk of advanced fibrosis in patients with chronic hepatitis C. Gastroenterology 2006;130:1679-87.